Last updated on April 2018

Novel INXN-4001 Triple Effector Plasmid in Heart Failure

Brief description of study

To evaluate the safety of retrograde coronary sinus infusion of a novel triple-effector plasmid (INXN-4001) in outpatient LVAD recipients as assessed by incidence of all study intervention - related adverse events occurring up to 6 months post-treatment

Clinical Study Identifier: NCT03409627

Contact Investigators or Research Sites near you

Start Over

Catherine MacDonald, BScN, MBA

University of Arizona Sarver Heart Center
Tucson, AZ United States
  Connect »